Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 2;13(6):825.
doi: 10.3390/pharmaceutics13060825.

Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment

Affiliations

Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment

Iris Neto et al. Pharmaceutics. .

Abstract

The antimicrobial activity of dehydroabietic acid (DHA) for its use as an antibiofilm agent was tested in this work. DHA was assayed against a collection of Gram-positive, Gram-negative sensitive and resistant bacteria and yeasts through the minimum inhibitory concentration (MIC), MIC with Bioburden challenge, minimum bactericidal concentration (MBC), minimum biofilm inhibitory concentration (MBIC), MBIC with Bioburden challenge and growth curve studies. Toxicological studies (Artemia salina, sulforhodamine B (SRB) assay) were done to assess if the compound had antimicrobial and not cytotoxic properties. Furthermore, microencapsulation and stability studies were carried out to evaluate the chemical behavior and stability of DHA. On MIC results, Gram-positive bacteria Staphylococcus aureus ATCC 1228 and Mycobacterium smegmatis ATCC 607 presented a high efficiency (7.81 µg/mL), while on Gram-negative bacteria the highest MIC value of 125 µg/mL was obtained by all Klebsiella pneumoniae strains and Escherichia coli isolate strain HSM 303. Bioburden challenge showed that MIC, MBIC and percentage biofilm inhibition (BI) values suffered alterations, therefore, having higher concentrations. MBIC values demonstrated that DHA has a higher efficiency against S. aureus ATCC 43866 with a percentage of BI of 75.13 ± 0.82% at 0.49 µg/mL. Growth curve kinetic profiles of DHA against S. aureus ATCC 25923 were observed to be bacteriostatic. DHA-alginate beads had a average size of 2.37 ± 0.20 and 2.31 ± 0.17 × 103 µm2 with an encapsulation efficiency (EE%) around 99.49 ± 0.05%, a protection percentage (PP%) of 60.00 ± 0.05% in the gastric environment and a protection efficiency (PE%) around 88.12 ± 0.05% against UV light. In toxicological studies DHA has shown IC50 of 19.59 ± 7.40 µg/mL and a LC50 of 21.71 ± 2.18%. The obtained results indicate that DHA is a promising antimicrobial candidate against a wide range of bacteria and biofilm formation that must be further explored.

Keywords: antimicrobial resistance; biofilm; dehydroabietic acid; infection; microencapsulation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structure of dehydroabietic acid (DHA).
Figure 2
Figure 2
Graphic representation of the growth curve study results of DHA against S. aureus ATCC 25923.
Figure 3
Figure 3
Digital images of (a) the empty alginate microspheres and (b) the DHA-alginate microspheres.

References

    1. World Health Organization . Antimicrobial Resistance: Global Report on Surveillance 2014. WHO; Geneva, Switzerland: 2014. p. 257.
    1. World Health Organization . Prevention of Hospital-Acquired Infections: A Practical Guide. WHO; Geneva, Switzerland: 2002. p. 64.
    1. O’Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. Wecome Trust; London, UK: 2014. p. 20.
    1. Sefton A.M. Mechanisms of antimicrobial resistance-Their clinical relevance in the new millennium. Drugs. 2002;62:557–566. doi: 10.2165/00003495-200262040-00001. - DOI - PubMed
    1. Patel R. Clinical impact of vancomycin-resistant enterococci. J. Antimicrob. Chemother. 2003;51:13–21. doi: 10.1093/jac/dkg272. - DOI - PubMed

LinkOut - more resources